Description: Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG.
Home Page: apontis-pharma.de
Alfred-Nobel-Str. 10
Monheim am Rhein,
40789
Germany
Phone:
49 2173 8955 4949
Officers
| Name | Title |
|---|---|
| Mr. Bruno Wohlschlegel | CEO & Chairman of Management Board |
| Mr. Thomas Milz | Chief Product Officer & Deputy Chairman of Management Board |
| Mr. Thomas Zimmermann | CFO & Member of Management Board |
| Mr. Harald Weyand | Head of Marketing |
| Ms. Susanne Böhm | Head of HR |
| Dr. Olaf Randerath | Head of Medicine |
| Dr. Susanne Endreß | Head of QA, Drug Safety & Regulatory Affairs |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.69 |
| Price-to-Sales TTM: | 2.0501 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 177 |